# A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

> **NCT00454636** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 158 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** Epirubicin
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00454636
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454636, "A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00454636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*